Загрузка...
Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins including the SRC family of kinases. Recently o...
Сохранить в:
| Опубликовано в: : | Sci Rep |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Publishing Group
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4544001/ https://ncbi.nlm.nih.gov/pubmed/26292723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep12949 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|